Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.